News about Quality / GMP

DCGI classifies 80 in-vitro diagnostic medical devices under Medical Devices Rules

DCGI classifies 80 in-vitro diagnostic medical devices under Medical Devices Rules

The Drugs Controller General (India) has classified around 80 in-vitro diagnostic medical devices including analysers, instruments and softwares, under the Medical Devices Rules, 2017, based on the intended use, risk associated with the device and other parameters

Quality / GMP | 26/07/2021 | By Darshana 275

CDSCO notifies 10 more medical devices testing laboratories for quality assurance

CDSCO notifies 10 more medical devices testing laboratories for quality assurance

In a bid to regulate all medical devices under Drugs and Cosmetics (D&C) Act in an effective way, the Central Drugs Standard Control Organisation (CDSCO) has notified ten more medical devices testing laboratories (MDTL) for carrying out evaluation of medical devices under the new Medical Devices (MD) Rules 2017 on behalf of manufacturers in the country

Quality / GMP | 13/07/2021 | By Darshana 667

NPPA fixes retail prices of 11 formulations under DPCO-2013

NPPA fixes retail prices of 11 formulations under DPCO-2013

The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 11 formulations under Drugs Prices Control Order (DPCO) - 2013 based on the decision of 89th authority meeting dated June 28, 2021

Quality / GMP | 12/07/2021 | By Darshana 211

CDSCO directs API manufacturers to file online applications for issuance of WC certificate on new SUGAM portal

CDSCO directs API manufacturers to file online applications for issuance of WC certificate on new SUGAM portal

The Central Drugs Standard Control Organisation (CDSCO) has directed active pharmaceutical ingredient (API) manufacturers to file online applications for issuance of written confirmation certificate (WCC) on the new SUGAM module. For exporting APIs to European Union (EU) countries, a written confirmation certificate is must

Quality / GMP | 09/07/2021 | By Darshana 1761

Lupin's Nagpur Facility Receives EIR from U.S. FDA

Lupin's Nagpur Facility Receives EIR from U.S. FDA

Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) after closure of the U.S. FDA inspection of its Nagpur, India facility. The inspection for the facility was carried out by the U.S. FDA between January 6, 2020 and January 10, 2020

Quality / GMP | 13/04/2020 | By Darshana 837

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members